JMJD2C-mediated Long Non-coding RNA MALAT1/microRNA-503-5p/SEPT2 Axis Worsens Non-small Cell Lung Cancer

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2022 Jan 20

PMID 35046387

Authors

Jun Zhang

Mingliang Wang

Jiashun Wang

Wendong Wang

Affiliations

Soon will be listed here.

Abstract

Jumonji domain containing protein 2C (JMJD2C) could epigenetically regulate cancer cells. We specifically explored the downstream mechanism of JMJD2C in non-small cell lung cancer (NSCLC) from the long non-coding RNA metastasis associated with lung adenocarcinoma transcript 1/microRNA-503-5p/septin 2 (MALAT1/miR-503-5p/SEPT2) axis. NSCLC clinical tissues were utilized to assess JMJD2C, MALAT1, miR-503-5p and SEPT2 levels. NSCLC cell lines (A549 and H1299) were applied for loss-of-function and gain-of-function tests to identify the functional roles of JMJD2C, MALAT1, miR-503-5p, and SEPT2. The interactions among JMJD2C, MALAT1, miR-503-5p, and SEPT2 were assessed. Augmented JMJD2C, MALAT1, and SEPT2 and reduced miR-503-5p levels were found in NSCLC. Depleting JMJD2C or MALAT1, or restoring miR-503-5p exerted anti-tumor effects on NSCLC cells in vitro and in vivo. JMJD2C is bound to the promoter of MALAT1. MALAT1 bound to miR-503-5p and miR-503-5p targeted SEPT2. Knocking down MALAT1 or SEPT2, or elevating miR-503-5p mitigated the pro-tumor effects of upregulated JMJD2C on NSCLC. It is evident that the JMJD2C-mediated MALAT1/miR-503-5p/SEPT2 axis takes part in the process of NSCLC and even worsens NSCLC.

Citing Articles

Decoding LncRNA in COPD: Unveiling Prognostic and Diagnostic Power and Their Driving Role in Lung Cancer Progression.

Sweef O, Mahfouz R, Tascioglu T, Albowaidey A, Abdelmonem M, Asfar M Int J Mol Sci. 2024; 25(16).

PMID: 39201688 PMC: 11354875. DOI: 10.3390/ijms25169001.

Jmjd2c maintains the ALDH cancer stemness with transcription factor SOX2 in lung squamous cell carcinoma.

Wang M, Hu Y, Cai F, Guo L, Mao Y, Zhang Y Cancer Biol Ther. 2024; 25(1):2373447.

PMID: 38975736 PMC: 11232651. DOI: 10.1080/15384047.2024.2373447.

LncRNA PGM5-AS1 inhibits non-small cell lung cancer progression by targeting miRNA-423-5p/SLIT2 axis.

Wang J, Ye J, Dang Y, Xu S Cancer Cell Int. 2024; 24(1):216.

PMID: 38902704 PMC: 11191156. DOI: 10.1186/s12935-024-03402-5.

The promotive role of lncRNA MIR205HG in proliferation, invasion, and migration of melanoma cells via the JMJD2C/ALKBH5 axis.

Liu Y, Wang S, Wei S, Qiu X, Mei Y, Yan L PLoS One. 2024; 19(1):e0290986.

PMID: 38252669 PMC: 10802967. DOI: 10.1371/journal.pone.0290986.

Association of long noncoding RNA MALAT1 with the radiosensitivity of lung adenocarcinoma cells via the miR-140/PD-L1 axis.

Li S, Xie Y, Zhou W, Zhou Q, Tao D, Yang H Heliyon. 2023; 9(6):e16868.

PMID: 37332979 PMC: 10272336. DOI: 10.1016/j.heliyon.2023.e16868.

References

Wei S, Wang K, Huang X, Zhao Z, Zhao Z . LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis. Int J Immunopathol Pharmacol. 2019; 33:2058738419859699. PMC: 6595645. DOI: 10.1177/2058738419859699. View

Cai B, Wang X, Bu Q, Li P, Xue Q, Zhang J . LncRNA AFAP1-AS1 Knockdown Represses Cell Proliferation, Migration, and Induced Apoptosis in Breast Cancer by Downregulating Via Sponging miR-497-5p. Cancer Biother Radiopharm. 2020; 37(8):662-672. DOI: 10.1089/cbr.2020.3688. View

Florczuk M, Szpechcinski A, Chorostowska-Wynimko J . miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives. Target Oncol. 2017; 12(2):179-200. DOI: 10.1007/s11523-017-0478-5. View

Chen S, Wang G, Tao K, Cai K, Wu K, Ye L . Long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 cooperates with enhancer of zeste homolog 2 to promote hepatocellular carcinoma development by modulating the microRNA-22/Snail family transcriptional repressor 1 axis. Cancer Sci. 2020; 111(5):1582-1595. PMC: 7226208. DOI: 10.1111/cas.14372. View

Xu D, Liu A, Wang X, Chen Y, Shen Y, Tan Z . Repression of Septin9 and Septin2 suppresses tumor growth of human glioblastoma cells. Cell Death Dis. 2018; 9(5):514. PMC: 5938713. DOI: 10.1038/s41419-018-0547-4. View

Tabchi S, Kassouf E, El Rassy E, Kourie H, Martin J, Campeau M . Management of stage III non-small cell lung cancer. Semin Oncol. 2017; 44(3):163-177. DOI: 10.1053/j.seminoncol.2017.10.009. View

Duan L, Perez R, Chastain 2nd P, Mathew M, Bijukumar D, Maki C . JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells. Oncogene. 2019; 38(28):5643-5657. DOI: 10.1038/s41388-019-0814-6. View

Zhang Z, Lin W, Lin Y, Kang M, Zhu J, Tong Z . Long intergenic non-coding RNA Linc00485 promotes lung cancer progression by modulating miR-298/c-Myc axis. J Cell Mol Med. 2020; 25(1):309-322. PMC: 7810966. DOI: 10.1111/jcmm.16036. View

Duma N, Santana-Davila R, Molina J . Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc. 2019; 94(8):1623-1640. DOI: 10.1016/j.mayocp.2019.01.013. View

10.

Wu X, Li R, Song Q, Zhang C, Jia R, Han Z . JMJD2C promotes colorectal cancer metastasis via regulating histone methylation of MALAT1 promoter and enhancing β-catenin signaling pathway. J Exp Clin Cancer Res. 2019; 38(1):435. PMC: 6819649. DOI: 10.1186/s13046-019-1439-x. View

11.

Young L, Hendzel M . The oncogenic potential of Jumonji D2 (JMJD2/KDM4) histone demethylase overexpression. Biochem Cell Biol. 2013; 91(6):369-77. DOI: 10.1139/bcb-2012-0054. View

12.

Wei L, Sun C, Zhang Y, Han N, Sun S . miR-503-5p inhibits colon cancer tumorigenesis, angiogenesis, and lymphangiogenesis by directly downregulating VEGF-A. Gene Ther. 2020; 29(1-2):28-40. DOI: 10.1038/s41434-020-0167-3. View

13.

Xing Z, Li S, Liu Z, Zhang C, Meng M, Bai Z . The long non-coding RNA LINC00473 contributes to cell proliferation via JAK-STAT3 signaling pathway by regulating miR-195-5p/SEPT2 axis in prostate cancer. Biosci Rep. 2020; 40(9). PMC: 7494984. DOI: 10.1042/BSR20191850. View

14.

Berry W, Janknecht R . KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res. 2013; 73(10):2936-42. PMC: 3655154. DOI: 10.1158/0008-5472.CAN-12-4300. View

15.

Watson A, Burrows M . Immunocytochemical and pharmacological evidence for GABAergic spiking local interneurons in the locust. J Neurosci. 1987; 7(6):1741-51. PMC: 6568883. View

16.

Wei Y, Liao Y, Deng Y, Zu Y, Zhao B, Li F . MicroRNA-503 Inhibits Non-Small Cell Lung Cancer Progression By Targeting PDK1/PI3K/AKT Pathway. Onco Targets Ther. 2019; 12:9005-9016. PMC: 6827514. DOI: 10.2147/OTT.S213059. View

17.

Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung G . The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2012; 73(3):1180-9. PMC: 3589741. DOI: 10.1158/0008-5472.CAN-12-2850. View

18.

Herbst R, Morgensztern D, Boshoff C . The biology and management of non-small cell lung cancer. Nature. 2018; 553(7689):446-454. DOI: 10.1038/nature25183. View

19.

Feng C, Zhao Y, Li Y, Zhang T, Ma Y, Liu Y . LncRNA MALAT1 Promotes Lung Cancer Proliferation and Gefitinib Resistance by Acting as a miR-200a Sponge. Arch Bronconeumol (Engl Ed). 2019; 55(12):627-633. DOI: 10.1016/j.arbres.2019.03.026. View

20.

Chen W, Zhao W, Chen S, Zhang L, Guo Z, Wang L . Expression and correlation of MALAT1 and SOX9 in non-small cell lung cancer. Clin Respir J. 2018; 12(7):2284-2291. DOI: 10.1111/crj.12906. View